Abstract
BackgroundBacterial conversion of ginsenosides is crucial for the health-promoting effects of ginsenosides. Previous studies on the biotransformation of ginsenoside Rb1 (Rb1) by gut bacteria have focused on the ginsenoside Rd (Rd) pathway (Rb1 → Rd → ginsenoside F2 (F2) → compound K (Cpd K)). This study aims to examine the gypenoside pathway in human gut bacteria in vitro.MethodsThe metabolic pathways of ginsenoside Rb1 and its metabolites ginsenoside Rd and gypenoside XVII in human gut bacteria were investigated by incubating the compounds anaerobically with pooled or individual gut bacteria samples from healthy volunteers. Ginsenoside Rb1, the metabolites generated by human gut bacteria, and degraded products in simulated gastric fluid (SGF) were qualitatively analyzed using an LC/MSD Trap system in the negative ion mode and quantitatively determined by HPLC-UV analysis.ResultsWhen incubated anaerobically with pooled gut bacteria, Rb1 generated five metabolites, namely Rd, F2, Cpd K, and the rare gypenosides XVII (G-XVII) and LXXV (G-LXXV). The gypenoside pathway (Rb1 → G-XVII → G-LXXV → Cpd K) was rapid, intermediate, and minor, and finally converted Rb1 to Cpd K via G-XVII → F2 (major)/G-LXXV (minor). Both the Rd and gypenoside pathways exhibited great inter-individual variations in age-and sex-independent manners (P > 0.05). Rb1 was highly acid-labile and degraded rapidly to form F2, ginsenoside Rg3, ginsenoside Rh2, and Cpd K, but did not generate the gypenosides in SGF. The formation of the gypenosides might be explained by the involvement of a gut bacteria-mediated enzymatic process.ConclusionsRb1 was metabolized to G-XVII, F2 (major) or G-LXXL (minor), and finally Cpd K by human gut bacteria in vitro.
Highlights
Bacterial conversion of ginsenosides is crucial for the health-promoting effects of ginsenosides
Hasegawa et al [17] proposed metabolism of Rb1 via the ginsenoside Rd (Rd) pathway by human intestinal bacteria in vitro, which was initiated at the C-20 glucose (Rb1 → Rd → ginsenoside F2 (F2) → Compound K (Cpd K)), and the gypenoside XVII (G-XVII) pathway, which was initiated by removal of the C-3 glucose (Rb1 → G-XVII → gypenoside LXXV (GLXXV) → Cpd K)
This study aims to examine the gypenoside pathway in human gut bacteria in vitro
Summary
Bacterial conversion of ginsenosides is crucial for the health-promoting effects of ginsenosides. This study aims to examine the gypenoside pathway in human gut bacteria in vitro. The bacterial metabolites are the main forms transported across the epithelial membrane and are most likely to be the real in vivo active forms [13]. This finding has led to research on microbial metabolism and the pharmacological activities of the resultant metabolites of ginsenosides including Rb1 [14,15,16]. The gypenoside pathway of Rb1 was only speculated from the results of TLC, and the data were not provided by the authors [18,19]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
